Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a ...

Novo Nordisk has taken the next step in selling its drugs directly to patients by pointing them to telehealth providers that ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

Novo Nordisk stock looks so cheap, any good news at all can make it pop.

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO stock is a Buy.

For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop.

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below historical averages.

Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy.

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli ...